Suppr超能文献

乌干达耐药结核病患者治疗延迟的预测因素。

Predictors of treatment delay among drug resistant tuberculosis patients in Uganda.

作者信息

Kasozi Nabukenya Diana, Charles Lwanga, JohnBosco Asiimwe, Henry Luzze

机构信息

Department of Statistical Methods & Actuarial Sciences, School of Statistics and Planning, College of Business & Management Sciences, Makerere University, Kampala, Uganda.

Department of Population Studies, School of Statistics and Planning, College of Business & Management Sciences, Makerere University, Kampala, Uganda.

出版信息

BMC Infect Dis. 2024 Dec 20;24(1):1452. doi: 10.1186/s12879-024-10339-7.

Abstract

BACKGROUND

Drug resistant tuberculosis (DR-TB) continues to be a significant global public health concern despite the availability of effective TB medicines. Equally, delayed DR-TB treatment initiation is associated with increased morbidity, amplified resistance, transmission risk and poor treatment outcomes. This study aimed to investigate treatment delays and identify predictors of delayed treatment initiation among DR-TB patients in Uganda.

METHOD

A retrospective study was conducted using routine DR-TB national case registration data between January 2012 and December 2019. Stata version 15 was used to run uni-variate analysis to describe patient characteristics using frequencies and percentages; bivariate analysis to identify significant differences in median times to treatment initiation; and logistic regression model was fitted, and adjusted odds ratio (AOR) with 95% confidence interval was used to identify factors associated with DR-TB treatment delay.

RESULTS

A total of 2,166 DR-TB patients were included in this study. The median treatment initiation delay was 10 days. Approximately 57% of DR-TB patients experienced delays in starting their treatment beyond the acceptable 7-day timeframe. Being diagnosed as RR-TB [AOR = 1.22; 95% CI: 1.08-1.37], and being a recurrent TB patient [AOR = 1.22; 95% CI: 1.01-1.47] were associated with treatment delays. Patients with previous history of 'lost to follow-up' (LTFU), failure and being diagnosed as Pre-XDR-TB were less inclined to delay DR-TB treatment.

CONCLUSION

Several DR-TB patients experienced treatment delay. The delay was significant among patients diagnosed as RR-TB and those with TB treatment history of recurrent TB. This highlights the need for heightened vigilance among healthcare workers when managing DR-TB patients with a history of past TB treatment and those diagnosed as RR-TB to minimize delays. Furthermore, future research should investigate a comprehensive list of variables influencing the timing of treatment initiation after diagnosis. An in-depth understanding of the effects of these factors can inform targeted interventions to optimize treatment strategies for improved DR-TB patient outcomes.

摘要

背景

尽管有有效的结核病药物,但耐多药结核病(DR-TB)仍然是一个重大的全球公共卫生问题。同样,耐多药结核病治疗开始延迟与发病率增加、耐药性增强、传播风险和治疗效果不佳有关。本研究旨在调查乌干达耐多药结核病患者的治疗延迟情况,并确定治疗开始延迟的预测因素。

方法

使用2012年1月至2019年12月期间耐多药结核病国家病例常规登记数据进行回顾性研究。使用Stata 15版进行单变量分析,用频率和百分比描述患者特征;进行双变量分析以确定治疗开始中位时间的显著差异;拟合逻辑回归模型,并使用95%置信区间的调整优势比(AOR)来确定与耐多药结核病治疗延迟相关的因素。

结果

本研究共纳入2166例耐多药结核病患者。治疗开始延迟的中位时间为10天。约57%的耐多药结核病患者在开始治疗时经历了超过可接受的7天时间框架的延迟。被诊断为RR-TB[AOR = 1.22;95% CI:1.08 - 1.37]以及为复发性结核病患者[AOR = 1.22;95% CI:1.01 - 1.47]与治疗延迟有关。有既往“失访”(LTFU)、治疗失败病史以及被诊断为Pre-XDR-TB的患者不太容易出现耐多药结核病治疗延迟。

结论

一些耐多药结核病患者经历了治疗延迟。在被诊断为RR-TB的患者以及有复发性结核病治疗史的患者中,延迟情况较为显著。这突出表明,医护人员在管理有既往结核病治疗史的耐多药结核病患者以及被诊断为RR-TB的患者时,需要提高警惕,以尽量减少延迟。此外,未来的研究应调查影响诊断后治疗开始时间的一系列变量。深入了解这些因素的影响可为有针对性的干预措施提供信息,以优化治疗策略,改善耐多药结核病患者的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60f1/11660896/8693a2046b6d/12879_2024_10339_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验